Therefore, targeting of TRIM25 via dual inhibition of NONO, on the one hand by restoring caspase-2-dependent NONO cleavage and on the other hand by impeding K63-linkage-dependent NONO ubiquitination, might turn out as a valid strategy for novel cancer therapy. The gene discussed is TRIM25; the disease is cancer.